Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Most sleep/insomnia-related and side-effect claims are not supported by the provided label excerpts; several patient-risk statements (falls/confusion, blurred vision, constipation, urinary retention, timing of sedation) are absent from the label text given. Only general statements about drowsiness and CNS depressant interaction are supported.
Category Scores
Accurate Statements
Hydroxyzine can cause drowsiness (warn patients about drowsiness and driving/operating machinery).
PRECAUTIONS: “Since drowsiness may occur… cautioned against driving a car or operating dangerous machinery while taking Atarax.”
Hydroxyzine’s effects are potentiated/impacted when used with central nervous system depressants; concomitant CNS depressant dosage should be reduced.
PRECAUTIONS: “THE POTENTIATING ACTION… MUST BE CONSIDERED… WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS… Therefore when… concomitantly… their dosage should be reduced.”
Common anticholinergic adverse reaction includes dry mouth.
ADVERSE REACTIONS: “Anticholinergic: Dry mouth.”
Reported CNS adverse reaction includes drowsiness (usually transitory).
ADVERSE REACTIONS: “Central Nervous System: Drowsiness is usually transitory…”
Drowsiness in elderly may involve confusion/oversedation; elderly should be started low and observed closely.
Geriatric Use: “Sedating drugs may cause confusion and over sedation in the elderly; elderly patients generally should be started on low doses… and observed closely.”
Unsupported Statements
Hydroxyzine is an antihistamine sometimes used off-label for sleep when insomnia is related to anxiety or itching/allergies.
Provided label excerpts describe anxiety relief and pruritus and sedation for premedication/following anesthesia, but do not state antihistamine/off-label use for insomnia.
Hydroxyzine is typically prescribed as a short-term or as-needed option for sleep.
No sleep-specific prescribing frequency/duration/as-needed guidance is present in the provided label excerpts.
Hydroxyzine is not a dedicated insomnia medication.
The provided label excerpts do not explicitly address whether it is “dedicated” for insomnia.
Hydroxyzine’s sedating effect starts within about 1 hour of taking a dose in many people.
Label excerpt only states effects usually noted within 15 to 30 minutes after oral administration; no “within about 1 hour” claim.
Taking hydroxyzine too late can increase the chance of residual morning sedation.
Label excerpts warn about drowsiness and driving while taking Atarax, but do not mention timing (“too late”) or residual morning sedation risk.
Common side effects include next-morning drowsiness or grogginess.
Label excerpt discusses drowsiness usually transitory, not next-morning drowsiness/grogginess.
Common side effects include dizziness.
Dizziness is not listed in the provided ADVERSE REACTIONS excerpt.
Common side effects include constipation.
Constipation is not listed in the provided ADVERSE REACTIONS excerpt.
Hydroxyzine can cause urinary retention.
Urinary retention is not listed in the provided ADVERSE REACTIONS excerpt.
Urinary retention from hydroxyzine is more likely in older adults.
No urinary retention or age-specific urinary risk is stated in the provided label excerpts.
Common side effects include blurred vision.
Blurred vision is not listed in the provided ADVERSE REACTIONS excerpt.
Because hydroxyzine has anticholinergic effects, older adults are more prone to falls.
Geriatric excerpt mentions confusion and over sedation, but does not mention falls.
Hydroxyzine may be a poor choice or needs extra caution in people with glaucoma, especially narrow-angle glaucoma.
Glaucoma/narrow-angle caution is not present in the provided label excerpts.
Hydroxyzine may be a poor choice or needs extra caution in people with trouble urinating or an enlarged prostate.
Trouble urinating/enlarged prostate caution is not present in the provided label excerpts.
Hydroxyzine may be a poor choice or needs extra caution in people with significant constipation.
Constipation is not identified in provided label excerpts as a relevant caution/condition.
Hydroxyzine may be a poor choice or needs extra caution in people with a history of confusion or falls.
Label excerpt supports confusion/over sedation in elderly, but does not mention history of confusion/falls as a separate caution category.
Hydroxyzine may be a poor choice or needs extra caution in people who need to drive or operate machinery the next morning.
Label warns against driving/operating dangerous machinery while taking Atarax, but does not specify “next morning”.
Hydroxyzine may be a poor choice or needs extra caution in people using other sedating medicines because it can add to sedation.
Label supports potentiating action with CNS depressants and advises reducing dosages; it does not describe “add to sedation” phrasing, nor “poor choice.”
Combining hydroxyzine with other central nervous system depressants (for example, alcohol, benzodiazepines, opioids, or other sedating antihistamines) increases the risk of excessive sedation.
Label mentions potentiation with CNS depressants and dose reduction; it does not list specific examples (alcohol/benzodiazepines/opioids/other sedating antihistamines) nor phrase “risk of excessive sedation.”
Combining hydroxyzine with other central nervous system depressants increases the risk of impaired coordination.
Impaired coordination is not stated in the provided label excerpts.
Combining hydroxyzine with other central nervous system depressants increases the risk of breathing problems in higher-risk patients.
Label excerpt says clinically significant respiratory depression has not been reported at recommended doses; no “breathing problems in higher-risk patients” statement.
Medication-by-medication review is important when combining hydroxyzine with other sedating agents.
No such general instruction is present in provided label excerpts.
Hydroxyzine is often chosen when insomnia is mixed with anxiety or when clinicians want a sedating antihistamine.
Label excerpts do not state insomnia use as a selection criterion or “often chosen” practice.
Prescription insomnia treatments (like low-dose doxepin and non-benzodiazepine “Z-drugs”) have different risk profiles than hydroxyzine.
Label excerpts do not compare hydroxyzine to other insomnia therapies or list those agents.
Prescription insomnia treatments may be preferred for long-term management depending on the person’s situation.
Provided label excerpt only addresses lack of systematic studies for long-term hydroxyzine antianxiety use (>4 months); it does not discuss preferences for other insomnia treatments.
The “best” choice for insomnia treatment depends on age, cause of insomnia, and tolerance of side effects.
No label support for insomnia decision-making framework or comparison criteria.
Contradictions
Important Omissions
Label-supported contraindications: prior hypersensitivity to hydroxyzine and contraindication in early pregnancy.
Importance:
Moderate
Label-supported indication scope (anxiety and pruritus; sedative use for premedication/following general anesthesia), which conflicts with the sleep/insomnia framing if used as the sole rationale.
Importance:
Moderate
In the provided label, efficacy for long-term antianxiety use (>4 months) has not been assessed by systematic clinical studies; the response does not mention this limitation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims about insomnia use and multiple adverse effects/cautions (e.g., urinary retention, falls, glaucoma, constipation, blurred vision, coordination/breathing risks, timing/residual sedation) are not supported by the provided label excerpts, which could mislead risk assessment and counseling. Some core warnings (drowsiness; CNS depressant potentiation; elderly confusion/oversedation) are supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Not Aligned
Primary Issue
Sleep/insomnia framing and multiple specific side-effect and risk statements are not supported by the provided label excerpts.
Suggested Improvement
Restrict claims to the label-supported indications (anxiety/pruritus and sedative premedication/post-anesthesia), supported adverse reaction (dry mouth; drowsiness transitory), and supported warnings (drowsiness; caution driving; potentiation with CNS depressants and dose reduction; nursing mothers not recommended; elderly confusion/oversedation). Avoid unsupported specifics (urinary retention, falls, glaucoma/enlarged prostate, constipation, blurred vision, impaired coordination/breathing problems, next-morning timing, and insomnia selection/comparative statements).